Primary Progressive Multiple Sclerosis Development Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
"Primary
Progressive Multiple Sclerosis Market - Global Industry Analysis,
Size, Share, Growth, Trends And Forecast, 2014 - 2020"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Multiple
sclerosis (MS), which is also referred as disseminated sclerosis, is
an inflammatory disease of the nervous system. It is mainly
characterized by the disruption of the nerve cells of the spinal cord
and the brain of an affected individual, which results in the loss of
ability to communicate along with various other physical, mental as
well as psychiatric problems. Primary progressive multiple sclerosis
(PPMS) is a type of MS in which the neurological functioning steadily
deteriorates with no distinct relapses (also known as attacks or
exacerbations) or fixed period of remissions. The rate of progression
of PPMS may differ from person to person as well as over time, that
may show signs of temporary improvement, however, the disease
progression remains consistent.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=220225
At
present, several forms of relapsing MS are increasingly affecting
large number of individuals worldwide, such as, secondary-progressive
MS, relapsing remitting MS, progressive relapsing MS and primary
progressive MS. These individuals continuously experience relapses,
which are distinct inflammatory attacks mainly on the myelin sheath
of the nerve fibers. In addition, PPMS is characterized by least
inflammation among different types of relapsing MS. PPMS also results
in very fewer brain lesions or plaques than in patients with other
forms of relapsing MS; these lesions also contain very small amount
inflammatory cells. Individuals suffering from PPMS have more lesions
on spinal cord than the brain. Thus, these differences have made PPMS
difficult to diagnose as well as treat than other forms of relapsing
MS. At present, different diagnostic tests are being utilized for
effectively diagnosing and employing proper treatment procedure in
place. Some of the diagnostic tests include Magnetic Resonance
Imaging (MRI) Scans, Lumbar Puncture and other simple electrical
stimulation tests. Major therapeutics available for the symptomatic
treatment of PPMS include Baclofen, Dantrolene, Oxybutynin,
Detrusitol, Amantadine, Modafinil, Clonazepam, Gabapentin and
Pregabalin. However, several manufacturers are developing specific
PPMS treatment drugs which are in different stages of clinical
trials, which include Fingolimod and Masitinib.
Some
of the major driving factors for the growth of this market include
increasing prevalence of neurological disorders, rising demand for
advanced therapeutics for the treatment of PPMS and increasing
awareness and affordability of the population in developing nations.
Multiple sclerosis is the most widespread neurological disorder that
affects individuals of any age, but is mainly diagnosed between 20 to
40 years of age. According to multiplesclerosis.net (Health Union,
U.S.), there are more than 2.5 million people suffering from multiple
sclerosis, which are at different stages of the disease. Among all
forms of MS, 10% to 15% individuals suffer from PPMS, which are
difficult to diagnose as well as treat; hence, high demand for
advanced therapeutics for its treatment will further boost the growth
of this market.
Geographically,
North America and Europe are expected to dominate the PPMS market.
Major factors that can be responsible for their dominance in this
market are high prevalence of MS and high demand for therapeutic
drugs for effective treatment of PPMS in these regions. According to
multiplesclerosis.net more than 500,000 people suffer from MS in
Europe and around 400,000 people suffer from it only in the U.S.
Thus, high prevalence rate of MS and PPMS will contribute towards the
growth of this market in the region. Some of the major players having
their drugs for SPMS in different phases of clinical trials, include,
F. Hoffmann-La Roche Ltd. and Innate Immunotherapeutics Limited.
This
research report analyzes this market on the basis of its market
segments, major geographies, and current market trends. Geographies
analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This report provides comprehensive
analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a
complete study of current trends in the market, industry growth
drivers, and restraints. It provides market projections for the
coming years. It includes analysis of recent developments in
technology, Porter’s five force model analysis and detailed
profiles of top industry players. The report also includes a review
of micro and macro factors essential for the existing market players
and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Comments
Post a Comment